Adherence to neoadjuvant therapy guidelines for locally advanced rectal cancers in a region with sociodemographic disparities - 26/07/21
Abstract |
Background |
Practice guidelines recommend neoadjuvant chemoradiation (NCR) for locally advanced rectal cancer (LARC). We examined guideline adherence in a healthcare system serving a region with socioeconomic disparities and poor cancer outcomes.
Methods |
Retrospective analysis of factors associated with guideline adherence.
Results |
63.1% of stage II/III LARC patients received NCR. Factors associated with adherence included white race (OR = 2.15, p = 0.024), private insurance (OR = 2.70, p = 0.005), employed status (OR = 2.30, p = 0.031), age at diagnosis (OR = 0.74, p = 0.032), appropriate local staging (OR = 9.17, p < 0.0001), and diagnosis later in the study period (OR per 1 year = 1.20, p = 0.006). By multivariate analysis, private insurance (OR = 2.51, p = 0.023), younger age (OR per 10 years = 0.72, p = 0.048) and appropriate local staging (OR = 6.67, p < 0.0001) were associated with adherence.
Conclusion |
Guideline adherence for LARC in our system is low and is impacted by employment, race and insurance status. Standard of care compliance remains an important target for improvement efforts in this underserved region of the nation’s Mid-South.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Highlights |
• | Guideline adherence for locally advanced rectal cancer is low in the region. |
• | This region is marked by socioeconomic disparities and poor rectal cancer outcomes. |
• | Factors such as employment and insurance influenced adherence to guidelines. |
• | Systemic factors such as surgeon characteristics also impacted compliance. |
• | Adherence improved over time but remains lower than expected. |
Keywords : Locally advanced rectal cancer, Guideline adherence, Guideline compliance, Neoadjuvant therapy, Disparities
Plan
Vol 222 - N° 2
P. 395-401 - août 2021 Retour au numéro
Article précédent
- Pathologic complete response is associated with decreased morbidity following rectal cancer resection
- Joshua H. Wolf, Ya-Ching Hung, Solange Cox, Blessing Aghedo, Arun Mavanur, Shane Svoboda, Christopher R. D’Adamo
- Delaying definitive resection in early stage (I/II) colon cancer appears safe up to 6 weeks
- Jesse T. Davidson, Jonathan S. Abelson, Sean C. Glasgow, Steven R. Hunt, Matthew G. Mutch, Paul E. Wise, Matthew L. Silviera, Radhika K. Smith
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?